The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP and continued the other NRTIs for a period of time, i.e. "staggered interruption"; and (3) started EFV-based regimens as an initial regimen (as controlled group).
Study Type
OBSERVATIONAL
Enrollment
559
Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
Bamrasnaradura Infectious Disease Institute
Nonthaburi, Thailand
Time to Virological failure
Virological failure was defined as either (1) two consecutive results of plasma HIV-1 RNA \>400 copies/ml or (2) plasma HIV-1 RNA \>1,000 copies/ml with genotypic resistance assay revealed NRTI or NNRTI resistance-associated mutations
Time frame: until end of study cohort
Virological suppression
Virological suppression was defined as having plasma HIV-1 RNA \<50 copies/ml
Time frame: 24 months
Median increase from baseline of CD4 cell count
Time frame: 24 months
Adverse events
Adverse events were defined as either (1) having more than grade 3 according to DAID AE Grading Table, or (2) having clinical events that leaded to changed antiretroviral medications
Time frame: until end of cohort
Clinical outcomes such as death, major opportunistic infections, immune recovery syndrome, non-AIDS events
Time frame: until end of cohort
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.